<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPARKINSONIAN DOPAMINERGICS" code="N04B-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or increase the psychotic disorders. When a treatment with neuroleptics is necessary for a parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of &quot;neuroleptic malignant syndrome&quot; (NMS)).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGICS, EXCEPT PARKINSON" code="G02CB-002" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism of the dopamine agonist and the neuroleptics</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reciprocal antagonism of the levodopa and the neuroleptics</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
